ATE363905T1 - 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs - Google Patents

2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs

Info

Publication number
ATE363905T1
ATE363905T1 AT04759913T AT04759913T ATE363905T1 AT E363905 T1 ATE363905 T1 AT E363905T1 AT 04759913 T AT04759913 T AT 04759913T AT 04759913 T AT04759913 T AT 04759913T AT E363905 T1 ATE363905 T1 AT E363905T1
Authority
AT
Austria
Prior art keywords
phenyl
imidazo
inhibitors
cancer
treatment
Prior art date
Application number
AT04759913T
Other languages
English (en)
Inventor
Michael Ameriks
Kristen Arienti
Frank Axe
J Breitenbucher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE363905T1 publication Critical patent/ATE363905T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04759913T 2003-04-17 2004-04-16 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs ATE363905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46354203P 2003-04-17 2003-04-17

Publications (1)

Publication Number Publication Date
ATE363905T1 true ATE363905T1 (de) 2007-06-15

Family

ID=33310791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759913T ATE363905T1 (de) 2003-04-17 2004-04-16 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs

Country Status (7)

Country Link
US (2) US7132440B2 (de)
EP (1) EP1613313B1 (de)
JP (1) JP4726235B2 (de)
AT (1) ATE363905T1 (de)
CA (1) CA2522562C (de)
DE (1) DE602004006852D1 (de)
WO (1) WO2004093873A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
DE102005035741A1 (de) * 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
US8912214B2 (en) * 2005-07-29 2014-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
AU2015256208B2 (en) * 2014-05-06 2020-01-02 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP6848015B2 (ja) * 2018-07-17 2021-03-24 コリア アトミック エナジー リサーチ インスティテュートKorea Atomic Energy Research Institute 放射性元素の標識方法、放射性標識化合物、及びそれを含む放射性元素標識キット

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346575A1 (de) 1983-12-23 1985-07-04 Dr. Karl Thomae Gmbh, 7950 Biberach Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
DK0841924T3 (da) * 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
EP1043998B1 (de) 1997-12-13 2007-03-07 Bristol-Myers Squibb Company VERWENDUNG VON PYRAZOLO [ 3,4-b] PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
MXPA00011470A (es) 1998-05-22 2002-10-17 Avanir Pharmaceuticals Analogos de bencimidazol como reguladores de la disminucion de ige.
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
GB9914825D0 (en) 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
US6759425B2 (en) * 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
EP1304371B1 (de) 2000-06-21 2007-01-03 Chugai Seiyaku Kabushiki Kaisha Cds1-knockout-mäusen und davon abgeleitete zelllinien
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
EA007339B1 (ru) 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
JP4637481B2 (ja) 2001-10-19 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
JP2006504660A (ja) 2002-07-31 2006-02-09 ユーロ−セルティーク エス.エイ. アリール置換ベンゾイミダゾール類およびナトリウムチャネルブロッカーとしてのそれらの使用
EP1558341A4 (de) 2002-11-01 2010-09-08 Paratek Pharm Innc Transkriptionsfaktor modulierendeverbindungen und ihre verwendung

Also Published As

Publication number Publication date
WO2004093873A1 (en) 2004-11-04
CA2522562C (en) 2013-09-03
US7132440B2 (en) 2006-11-07
US7687639B2 (en) 2010-03-30
EP1613313A1 (de) 2006-01-11
US20060252793A1 (en) 2006-11-09
JP2006523712A (ja) 2006-10-19
EP1613313B1 (de) 2007-06-06
US20040214857A1 (en) 2004-10-28
DE602004006852D1 (de) 2007-07-19
JP4726235B2 (ja) 2011-07-20
CA2522562A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
DE60221866D1 (de) 2-PHENYL BENZIMIDAZOLE UND IMIDAZO-i4,5ö-PYRIDINE ALS CDS1/CHK2-INHIBITOREN UND ADJUVANTIEN IN DER CHEMOTHERAPIE ODER STRAHLUNGSTHERAPIE ZUR BEHANDLUNG VON KREBS
ATE365165T1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DK1379510T3 (da) Aryl- og heteroarylurinstof Chk1-inhibitorer til anvendelse som radiosensibilisatorer og kemosensibilisatorer
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DE60213842D1 (de) Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
TW200714604A (en) Substituted heterocycles and the uses thereof
ATE300529T1 (de) Imidazolderivate als raf-kinase-inhibitoren
DE60220290D1 (de) Pyridinderivate als inhibitoren der raf-kinase
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
ATE380807T1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
DE50310516D1 (de) Fredericamycin-derivate
DE602004006852D1 (de) 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DE602005027739D1 (de) Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
DE602005027728D1 (de) Benzodiazepin-Derivate als ROCK-Kinasen Hemmer
MXPA05010975A (es) Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
ATE527264T1 (de) Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
PT1551850E (pt) 2 oxo-voruscharina e seus derivados

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties